FOCUS: HEALTHCARE PR - A new pill to swallow. A further layer of healthcare regulation will necessitate greater levels of pre-launch PR for new drugs. Nick Purdom reports

Contrary to its friendly-sounding acronym, NICE - the National Institute of Clinical Excellence - could be anything but good news for pharmaceutical companies and their PR agencies. If a drug fails to win approval from NICE for NHS prescription by GPs its earnings potential could be severely diminished.

by NICK PURDOM

Sign in to continue

Sign in

Sign in

Trouble signing in?

Reset password: Click here

US and Asia
subscriptions@prweek.com
+001 (800) 558-1708

UK & Europe
support@prweek.com
+44 (0)20 8267 8121

Register

Don't have an account? Complete easy registration and receive:

  • Limited Article Views (Excludes Subscriber Only Content)
  • Select Newsletters (Excludes Subscriber Only Bulletins)

Register Now

Register

FREE

  • Limited free articles a month
  • Limited number of free email bulletins

Register Now

Subscribe

To receive full access to PRWeek's content subscribe today and receive:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Agency Business Report, annual Salary Survey, Power List, 40 Under 40, & Best Places to Work, and more

Subscribe Options

Start your free trial 

Enjoy these subscriber-exclusive benefits:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Power Book and Top 150 UK Agency Business Report

Join today

Need to activate your subscription?

Domain/Group Subscriptions
Click here >>

Individual Subscriptions
Click here >>

Need to activate your Subscription

Company Wide Subscriptions
Click here >>

 UK Individual Subscribers
Click here >>